Bringing Polygenics Into Cardiovascular Disease Diagnosis

Effective Tool To Measure Lifetime Risk Of CHD From Polygenics Technology Innovator

GENinCode’s mission as a clinical-genetic diagnostic company is to apply a combination of polygenics, a proprietary bioinformatics platform and AI to risk-assess and prevent cardiovascular disease. The company set a UK precedent in being the first to have a CVD commercial polygenic test implemented in the NHS and keenly awaits another milestone, US 510k clearance in 2024.

Cardiology
• Source: Shutterstock

Ten years ago, few scientific papers were being issued on polygenics, a branch of science that assesses an individual’s genetic variants to predict the heritable risk of developing a particular disease over their lifetime.

This year, it is estimated that over 2,000 international studies will be published, said Matthew Walls, CEO of UK AIM-listed GENinCode Plc. “GENinCode has been in this field since 2007...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.